GILEAD SCIENCES, INC. is 23.6x more valuable than Immunovant, Inc. by market capitalization ($151.05 B vs $6.40 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IMVT | GILD |
|---|---|---|
| Market cap | $6.40 B | $151.05 B |
| US-listed rank | #1219 | #99 |
| Revenue (latest FY) | - | $29.44B |
| Net income (latest FY) | -$505.61M | $8.51B |
| Net margin | - | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 611 | 981 |
GILEAD SCIENCES, INC. is 23.6x more valuable than Immunovant, Inc. by market capitalization ($151.05 B vs $6.40 B).
Full pages: Immunovant, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.